3F-NEB

3F-NEB
Legal status
Legal status
Identifiers
  • 2-(ethylamino)-1-(3-fluorophenyl)butan-1-one
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H16FNO
Molar mass209.264 g·mol−1
3D model (JSmol)
  • CCC(C(=O)C1=CC(=CC=C1)F)NCC
  • InChI=1S/C12H16FNO/c1-3-11(14-4-2)12(15)9-6-5-7-10(13)8-9/h5-8,11,14H,3-4H2,1-2H3
  • Key:FLFAFGGBRUXYBD-UHFFFAOYSA-N

3-Fluoro-N-ethylbuphedrone (3F-NEB) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It was first identified in Sweden in 2021.

Pharmacology

Pharmacodynamics

In vivo, 3F-NEB acts as a potent inhibitor of the dopamine transporter, exhibiting more than 100-fold selectivity over the serotonin transporter. Administration of 3 milligrams rapidly increased extracellular dopamine levels in the nucleus accumbens, of the rat. At the behavioural level, 3F-NEB caused a dose-dependent increase in motor activity at doses of 10–30 mg/kg, with the highest doses inducing anxiety-like effects.

See also

References

  1. 1 2 Pain S, Nadal-Gratacós N, De Macedo M, Lardeux V, Mata S, Puigseslloses P, et al. (February 2026). "Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone". European Journal of Pharmacology. 1015 178570. doi:10.1016/j.ejphar.2026.178570. hdl:20.500.14342/5980. PMID 41554370.
  2. ↑ European Monitoring Centre for Drugs and Drug Addiction. (June 2022). New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System. European Monitoring Centre for Drugs and Drug Addiction. doi:10.2810/396103. ISBN 978-92-9497-737-3.
  3. ↑ Kuropka P, Zawadzki M, Szpot P (September 2022). "A review of synthetic cathinones emerging in recent years (2019-2022)". Forensic Toxicology. 41 (1): 25–46. doi:10.1007/s11419-022-00639-5. PMC 9476408. PMID 36124107.